Quick Update from ASCO

Article

I apologize if it seems that the updates about ASCO have been slow in coming. This is mostly because the lung cancer program this year has most of the higher profile presentations occurring in the second half of the meeting, which we're just getting into. And, truth be told, this isn't going to be a blockbuster year for developments in lung cancer. But let's review what we've found out about thus far.

Dr. Suresh Ramalingam on Personalizing First Line Therapy for Advanced NSCLC: Podcast Available

Article

I'm very pleased to offer the excellent podcast produced from the recent webinar by Dr. Suresh Ramalingam, a leader in the lung cancer field who heads the Thoracic Oncology Program at Emory University in Atlanta. He's also a good friend I've known since our fellowship training days, and he was kind and generous enough to refuse the honorarium we offered for his participation, instead requesting that it be donated back and used for other GRACE programs. Instead, he was happy to do this entirely out of a commitment to the lung cancer community.

Podcast by Dr. Camidge on ALK Rearrangements and a New Era of Molecular Oncology

Article

Last week, Dr. Ross Camidge from the University of Colorado joined me on a webinar entitled "One Size Does Not Fit All" in which he discussed the early work on ALK rearrangements and the novel agent PF-02341066 (now known as crizotinib) in particular, and the new era of molecularly defined practice of oncology in particular. This story has been widely considered to be among the most important in the field of lung cancer over the last few years, and Dr. Camidge did not disappoint.